Literature DB >> 19006770

Positron emission tomography/computed tomography for staging and restaging of head and neck cancer: comparison with positron emission tomography read together with contrast-enhanced computed tomography.

Gerhard W Goerres1, Bernhard Schuknecht, Daniel T Schmid, Sandro J Stoeckli, Thomas F Hany.   

Abstract

This retrospective study aimed to describe the differences between image readings done with combined positron emission tomography/computed tomography (PET/CT) and PET read together with contrast-enhanced CT (ceCT) in patients with squamous cell carcinoma of the head and neck. In 46 patients, no differences were found between the two readings for assessing infiltration of adjacent structures (P=.63), transgression of the midline (P=.67), lymph node involvement (P=.32), and T- and N stage. PET/CT and PET read together with ceCT have comparable diagnostic yield.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19006770     DOI: 10.1016/j.clinimag.2008.04.012

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  3 in total

1.  Use of diffusion-weighted imaging (DWI) in PET/MRI for head and neck cancer evaluation.

Authors:  Marcelo A Queiroz; Martin Hüllner; Felix Kuhn; Gerhardt Huber; Christian Meerwein; Spyros Kollias; Gustav von Schulthess; Patrick Veit-Haibach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-05       Impact factor: 9.236

2.  Staging primary head and neck cancers with (18)F-FDG PET/CT: is intravenous contrast administration really necessary?

Authors:  Keisuke Yoshida; Akiko Suzuki; Toshiyuki Nagashima; Jin Lee; Choichi Horiuchi; Mamoru Tsukuda; Tomio Inoue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-08       Impact factor: 9.236

3.  Ultrasound fusion imaging with real-time navigation for the surveillance after endovascular aortic aneurysm repair.

Authors:  Jin Hyun Joh; Sang-Ah Han; Sang-Hyun Kim; Ho-Chul Park
Journal:  Ann Surg Treat Res       Date:  2017-05-29       Impact factor: 1.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.